A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 12-Week Efficacy, Safety, and Speed of Response from a Randomized, Double-Blinded Trial

Psoriasis

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Br J Dermatol.

Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K, IXORA-R Study Group

doi: 10.1111/bjd.19509.

Psoriasis

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

Lancet.

Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D

doi: 10.1016/

Psoriasis

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial

Br J Dermatol.

Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L

doi: 10.1111/bjd.15750.

Psoriasis

Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)

Br J Dermatol.

Paller AS, Seyger MMB, Magariños GA, Bagel J, Pinter A, Cather J, Keller S, Capriles CR, Lima RG, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K, IXORA-PEDS study group.

doi: 10.1111/bjd.19147.

Psoriasis

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Lancet.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H

doi: 10.1016/S0140-6736(18)31713-6.

COMMENTED

Psoriasis

Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis

Click to enlarge

doi: 10.1111/bjd.16736.

Psoriasis

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Lancet

Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M

doi: 10.1016/S0140-6736(21)00125-2

Psoriasis

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA Dermatol.

Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG

doi: 10.1001/jamadermatol.2020.0723.

COMMENTED

Psoriasis

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Lancet.

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C

doi: 10.1016/S0140-6736(19)30952-3.

Related content

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial

Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial